From Name:
From Email:
To Name:
To Email:

Optional Message:

PARP inhibitors reemerge as treatment for serous ovarian cancer

from OncLive

The genomic instability inherent in serous ovarian cancer poses treatment challenges, but it also represents a target which can be exploited through the use of PARP inhibitors, according to Michael Birrer, M.D., Ph.D., professor of Medicine, Harvard Medical School, and director of Gynecologic Medical Oncology at Massachusetts General Hospital in Boston. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063